Astorne Capital, which previously held a 1.15 percent stake in Sai Parenterals Limited, is no longer listed among its public shareholders, indicating either a complete sale or a reduction to below the 1 percent reporting threshold.
A diversified pharmaceutical formulations company, Sai Parenteral's specializes in the research, development, and manufacturing of injectable and parenteral drugs for multiple therapeutic areas. Incorporated in 2001, the company maintains expertise in complex formulation technologies and operates integrated manufacturing facilities. It serves both domestic and international markets, with a focus on quality compliance and advanced pharmaceutical solutions across its product portfolio.
Astorne Capital is a Singapore-based variable capital company managed by fund manager Prosperitas Capital, investing in Indian listed and SME equities.